

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

August 8, 2025

Consolidated Financial Results for the Three Months Ended June 30, 2025 (Under Japanese GAAP)



Company name: Kitazato Corporation
 Listing: Tokyo Stock Exchange
 Securities code: 368A
 URL: <https://www.kitazato.co.jp>
 Representative: Futoshi Inoue, President, CEO
 Inquiries: Masanobu Suzuki, Director, General Manager of Corporate Planning Department
 Telephone: +81-545-65-7122
 Scheduled date to commence dividend payments: —
 Preparation of supplementary material on financial results: None
 Holding of financial results briefing: None

(Yen amounts are rounded down to millions, unless otherwise noted.)

1. Consolidated financial results for the three months ended June 30, 2025 (from April 1, 2025 to June 30, 2025)

(1) Consolidated operating results (cumulative)

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
Three months ended	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
June 30, 2025	2,434	3.6	1,195	(4.2)	1,125	(11.1)	745	(9.3)
June 30, 2024	2,348	—	1,247	—	1,265	—	821	—

Note: Comprehensive income For the three months ended June 30, 2025: ¥745 million [(9.3)%]
 For the three months ended June 30, 2024: ¥821 million [—%]

	Basic earnings per share	Diluted earnings per share
Three months ended	Yen	Yen
June 30, 2025	18.64	—
June 30, 2024	20.55	—

Notes: 1. Since the Company did not prepare quarterly consolidated financial statements for the three months ended June 30, 2023, year-on-year changes for the three months ended June 30, 2024 have been omitted.
 2. The Company conducted a 200,000-for-1 stock split of its common shares on February 8, 2025. Basic earnings per share have been calculated based on the assumption that the above stock split was conducted at the beginning of the previous fiscal year.

(2) Consolidated financial position

	Total assets	Net assets	Equity-to-asset ratio
As of	Millions of yen	Millions of yen	%
June 30, 2025	18,471	17,355	94.0
March 31, 2025	19,748	18,249	92.4

Reference: Equity

As of June 30, 2025: ¥17,355 million
 As of March 31, 2025: ¥18,249 million

2. Cash dividends

	Annual dividends per share				
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended March 31, 2025	0.00	0.00	0.00	41.00	41.00
Fiscal year ending March 31, 2026	—				
Fiscal year ending March 31, 2026 (Forecast)		0.00	—	41.00	41.00

Note: Revisions to the forecast of cash dividends most recently announced: None

3. Consolidated financial result forecasts for the fiscal year ending March 31, 2026 (from April 1, 2025 to March 31, 2026)

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Basic earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Full year	10,602	2.9	5,374	(7.1)	5,267	(8.7)	3,498	(7.7)	87.46

Note: Revisions to the forecast of financial results most recently announced: None

*** Notes**

- (1) Significant changes in the scope of consolidation during the period: None
- (2) Adoption of accounting treatment specific to the preparation of quarterly consolidated financial statements: Yes

Note: For details, please see page 8 of the Attachments: “2. Quarterly Consolidated Financial Statements and Principal Notes (3) Notes to Quarterly Consolidated Financial Statements (Adoption of accounting treatment specific to the preparation of quarterly consolidated financial statements).”

- (3) Changes in accounting policies, changes in accounting estimates, and restatement
- (i) Changes in accounting policies due to revisions to accounting standards and other regulations: None
- (ii) Changes in accounting policies due to other reasons: None
- (iii) Changes in accounting estimates: None
- (iv) Restatement: None

- (4) Number of issued shares (common shares)

- (i) Total number of issued shares at the end of the period (including treasury shares)

As of June 30, 2025	40,000,000 shares
As of March 31, 2025	40,000,000 shares

- (ii) Number of treasury shares at the end of the period

As of June 30, 2025	– shares
As of March 31, 2025	– shares

- (iii) Average number of shares outstanding during the period (cumulative from the beginning of the fiscal year)

Three months ended June 30, 2025	40,000,000 shares
Three months ended June 30, 2024	40,000,000 shares

Note: The Company conducted a 200,000-for-1 stock split of its common shares on February 8, 2025. “Average number of shares outstanding during the period” for the three months ended June 30, 2024 has been calculated based on the assumption that the above stock split was conducted at the beginning of the previous fiscal year.

- * Review of the Japanese-language originals of the attached consolidated quarterly financial statements by certified public accountants or an audit firm: Yes (voluntary)

- * Proper use of earnings forecasts, and other special matters
(Other special matters)

The quarterly consolidated financial statements for the first quarter of the previous fiscal year which ended on March 31, 2025 and for the three months ended June 30, 2024, have not been reviewed by an audit firm.

(Notes on forward-looking statements)

The financial results forecasts and other forward-looking statements contained in these documents are based on information currently available to the Company and certain assumptions that the Company has deemed reasonable. The information is not intended as a guarantee that the Company will achieve these targets. Actual financial results may differ significantly due to various factors.

Table of Contents - Attachments

1. Overview of Operating Results, Etc.	2
(1) Overview of Operating Results for the Three Months Ended June 30, 2025	2
(2) Overview of Financial Position for the Three Months Ended June 30, 2025	3
(3) Explanation of Consolidated Financial Results Forecast and Other Forward-looking Information	3
2. Quarterly Consolidated Financial Statements and Principal Notes	4
(1) Quarterly Consolidated Balance Sheet	4
(2) Quarterly Consolidated Statements of Income and Comprehensive Income	6
(3) Notes to Quarterly Consolidated Financial Statements	8
(Adoption of accounting treatment specific to the preparation of quarterly consolidated financial statements)	8
(Notes on segment information, etc.)	8
(Notes in case of significant changes in shareholders' equity)	8
(Notes on going concern assumption)	8
(Notes on statement of cash flow)	8

1. Overview of Operating Results, Etc.

(1) Overview of Operating Results for the Three Months Ended June 30, 2025

During the three months ended June 30, 2025 (from April 1, 2025 to June 30, 2025), the Japanese economy saw gradual improvements in the employment and income environment, and a gradual recovery in the personal consumption as a whole, despite the impacts of rising prices. However, the outlook remains uncertain due to concerns regarding soaring resource prices caused by international instability and fluctuations in financial and capital markets.

In the infertility treatment field, the rise in demand for infertility treatment brought on by global lifestyle changes, declining birthrates and shrinking population is driving overall market growth. In addition, we believe that the increase in social understanding and recognition of assisted reproductive technology, and improvements in the government's support policies and compensation programs, are important factors in driving market growth.

In this business environment, the Kitazato Group develops and manufactures products for infertility treatment and delivers proprietary products across global markets. Specializing in reproductive technologies in artificial insemination, in vitro fertilization, cell cryopreservation, and regenerative medicine, we supply products that respond to market needs.

The Group's consolidated financial results for the three months ended June 30, 2025 are as below.

<Net sales>

The Group's net sales for the three months ended June 30, 2025 amounted to ¥2,434 million (up 3.6% year on year).

In Japan, net sales amounted to ¥895 million (up 3.6% year on year) as the sales of new products and improved products of oocyte retrieval needles, and catheters remained strong.

Overseas, net sales amounted to ¥1,538 million (up 3.6% year on year) thanks to the launch of new products, oocyte/embryo vitrification solution, embryo transfer catheter, and the progress in acquiring new customers in Europe, and the steady progress in acquiring customers in India as well, while the sales in other regions decreased due to the inventory adjustment in Thailand and Taiwan as well as the changes in distributors in Canada, etc.

[Net sales by product category]

(Millions of Yen)				
	First quarter of the fiscal year ended March 31, 2025 (results)	First quarter of the fiscal year ending March 31, 2026 (results)	Change	Percentage change
Net sales	2,348	2,434	85	103.6%
Media	849	923	74	108.7%
CryoDevices	638	563	(74)	88.3%
Medical devices	534	606	72	113.5%
Micro Tools	283	282	(0)	99.9%
Other	43	56	13	130.1%

[Net sales by region]

(Millions of Yen)

	First quarter of the fiscal year ended March 31, 2025 (results)	First quarter of the fiscal year ending March 31, 2026 (results)	Change	Percentage change
Net sales	2,348	2,434	85	103.6%
Japan	864	895	31	103.6%
Overseas	1,484	1,538	53	103.6%
Europe	769	844	74	109.7%
U.S.A.	228	242	13	106.0%
China	123	133	9	107.7%
India	66	145	78	218.5%
Other	296	173	(123)	58.5%

<Profit>

Gross profit amounted to ¥1,568 million (up 2.0% year on year) thanks to an increase of net sales, despite the increase in the cost of sales ratio caused by changes in product mix, etc.

Operating profit amounted to ¥1,195 million (down 4.2% year on year) due to exhibition expenses for academic conferences, etc. and an increase in remuneration payments associated with certification.

Ordinary profit amounted to ¥1,125 million (down 11.1% year on year) due to the recording of listing expenses, etc. Profit attributable to owners of parent amounted to ¥745 million (down 9.3% year on year).

(2) Overview of Financial Position for the Three Months Ended June 30, 2025

Total assets as of June 30, 2025 amounted to ¥18,471 million, marking a ¥1,277 million decrease compared to the end of the previous fiscal year. This was mainly due to a decrease of ¥925 million in cash and deposits.

Total liabilities amounted to ¥1,116 million, marking a ¥382 million decrease compared to the end of the previous fiscal year. This was mainly due to a decrease of ¥511 million in income taxes payable.

Total net assets amounted to ¥17,355 million, marking a ¥894 million decrease compared to the end of the previous fiscal year. This was due to a decrease of ¥1,640 million in dividend payments, despite an increase of ¥745 million from profit attributable to owners of parent.

(3) Explanation of Consolidated Financial Results Forecast and Other Forward-looking Information

The full-year consolidated financial results forecast remains unchanged from the forecast announced on June 25, 2025.

2. Quarterly Consolidated Financial Statements and Principal Notes

(1) Quarterly Consolidated Balance Sheet

(Millions of yen)

	As of March 31, 2025	As of June 30, 2025
Assets		
Current assets		
Cash and deposits	11,460	10,535
Accounts receivable - trade	1,459	905
Merchandise and finished goods	388	479
Work in process	487	552
Raw materials and supplies	914	961
Other	124	126
Total current assets	14,835	13,560
Non-current assets		
Property, plant and equipment		
Buildings and structures	2,110	2,118
Machinery, equipment and vehicles	252	251
Land	2,024	2,024
Construction in progress	711	705
Other	392	423
Accumulated depreciation	(939)	(973)
Total property, plant and equipment	4,552	4,548
Intangible assets		
Other	61	55
Total intangible assets	61	55
Investments and other assets		
Deferred tax assets	188	192
Other	111	114
Total investments and other assets	300	306
Total non-current assets	4,913	4,910
Total assets	19,748	18,471

(Millions of yen)

	As of March 31, 2025	As of June 30, 2025
Liabilities		
Current liabilities		
Accounts payable - trade	252	215
Income taxes payable	897	385
Provision for bonuses	59	33
Provision for product warranties	5	5
Other	204	384
Total current liabilities	1,419	1,024
Non-current liabilities		
Other	79	91
Total non-current liabilities	79	91
Total liabilities	1,499	1,116
Net assets		
Shareholders' equity		
Share capital	10	10
Retained earnings	18,239	17,345
Total shareholders' equity	18,249	17,355
Total net assets	18,249	17,355
Total liabilities and net assets	19,748	18,471

(2) Quarterly Consolidated Statements of Income and Comprehensive Income

Quarterly Consolidated Statement of Income

Three Months Ended June 30

(Millions of yen)

	For the three months ended June 30, 2024	For the three months ended June 30, 2025
Net sales	2,348	2,434
Cost of sales	810	865
Gross profit	1,538	1,568
Selling, general and administrative expenses	290	373
Operating profit	1,247	1,195
Non-operating income		
Interest income	0	0
Dividend income	0	–
Foreign exchange gains	20	–
Other	0	1
Total non-operating income	20	1
Non-operating expenses		
Interest expenses	0	0
Foreign exchange losses	–	20
Listing expenses	2	49
Other	0	–
Total non-operating expenses	2	70
Ordinary profit	1,265	1,125
Extraordinary income		
Gain on sale of non-current assets	–	0
Total extraordinary income	–	0
Extraordinary losses		
Loss from money transfer scam	25	–
Total extraordinary losses	25	–
Profit before income taxes	1,239	1,126
Income taxes - current	419	384
Income taxes - deferred	(2)	(3)
Total income taxes	417	380
Profit	821	745
Profit attributable to owners of parent	821	745

Quarterly Consolidated Statement of Comprehensive Income

Three Months Ended June 30

(Millions of yen)

	For the three months ended June 30, 2024	For the three months ended June 30, 2025
Profit	821	745
Comprehensive income	821	745
Comprehensive income attributable to		
Comprehensive income attributable to owners of parent	821	745

(3) Notes to Quarterly Consolidated Financial Statements

The quarterly consolidated financial statements have been prepared in accordance with Article 4, Paragraph 1 of the Standards for Preparation of Quarterly Financial Statements, etc. of the Tokyo Stock Exchange, Inc. and the accounting standards for quarterly financial statements that are generally accepted in Japan (provided, however, that the omission of a statement prescribed in Article 4, Paragraph 2 of the Standards for Preparation of Quarterly Financial Statements, etc. has been applied).

(Adoption of accounting treatment specific to the preparation of quarterly consolidated financial statements)

(Calculation of tax expenses)

Regarding tax expenses, the Company reasonably estimates an effective tax rate after applying tax effect accounting to profit before income taxes for the fiscal year in which the first quarter of the fiscal year ending March 31, 2026 is included, and calculates tax expenses by multiplying quarterly profit before income taxes by such estimated effective tax rate. However, if the estimated effective tax rate cannot be used, the statutory effective tax rate is used instead.

(Notes on segment information, etc.)

Segment information has been omitted as the Group operates only a single segment in the medical devices business.

(Notes in case of significant changes in shareholders' equity)

Not applicable.

(Notes on going concern assumption)

Not applicable.

(Notes on statement of cash flow)

The Company has not prepared a quarterly consolidated statement of cash flow for the three months ended June 30, 2025. Depreciation (including amortization related to intangible assets) for the three months ended June 30 is as follows.

	For the three months ended June 30, 2024	For the three months ended June 30, 2025
Depreciation	¥41 million	¥43 million